Drug discovery biotech firm Chemotargets, a CataloniaBio & HealthTech member, and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical needs in different fields including cancer.
Chemotargets develops computational platforms for the design, optimization and safety evaluation of drugs. The biotech firm’s cutting-edge computational technologies can rapidly design potential new drug candidates for therapeutic targets that are difficult to treat and for which no identified drugs currently exist. The new partnership will leverage the CRG’s fundamental knowledge on the complexity of life, as well as its expertise in identifying potential new therapeutic targets in emerging fields of cancer biology. 70% of the CRG’s projects with translational potential focus on the validation of new therapeutic targets for the treatment of different diseases such as cancer, fibrosis, eye diseases, blood diseases or diseases that cause inflammation.
"We welcome this collaboration and look forward to working with the CRG on several levels. In addition to world-class fundamental biology, the infrastructure to rapidly design medications specific for the phenotype and genotype of both disease and patient in collaboration with the CRG brings a critical new dimension to Chemotargets’ growing internal pipeline.” Dr Scott Boyer, CEO, Chemotargets.
Chemotargets was founded in 2006 as a spin-off of the systems pharmacology research group of Dr. Jordi Mestres under the auspices of the IMIM Hospital del Mar Medical Research Institute.
Comments